SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trillium Therapeutics -- Ignore unavailable to you. Want to Upgrade?


To: Miljenko Zuanic who wrote (265)2/22/2019 3:13:01 PM
From: scaram(o)uche  Respond to of 294
 
Well, one take-home from the publication that Tuck just pointed to is that CD47 blockade might inhibit TILs.

Sure, passive blockade might have a number of applications. That's what Nic should have been investing in.... preclinical models apart from cancer, rather than fluorinated crap.



To: Miljenko Zuanic who wrote (265)2/28/2019 3:56:10 PM
From: semi_infinite   Read Replies (2) | Respond to of 294
 
20+ abstracts at AACR when cd47 used in search. Interesting one from Arch Onco regarding IgG2. Trillium is getting lost in the crowd and you will probably get your 0.6x price soon.

abstractsonline.com!/6812/presentations/cd47/1